Lumenis Ltd., the world’s largest energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, today announced that the FDA has granted De Novo authorization for Lumenis’ newest IPL device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD).
Baring Private Equity Asia Announces Agreement to Sell Lumenis’ Surgical Business to Boston Scientific for $1.07 bln
Baring Private Equity Asia (BPEA) and Lumenis announced today that they have entered into a definitive agreement to sell the Lumenis Surgical Business to Boston Scientific (NYSE: BSX) in a transaction valued at USD1.07 billion, subject to closing adjustments.
Lumenis Unveils NuEra™ tight, Its High Power, Temperature-Controlled Top to Toe Radio Frequency Skin Laxity and Cellulite Treatment, at the 2018 Aesthetic Show
Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, is excited to announce its newest launch, NuEra tight– a non-invasive, intelligent temperature-controlled technology for both superficial and deep heating that treats a variety of conditions such as skin laxity and the appearance of cellulite.
Lumenis Exhibits Innovative Energy-based Technologies and the Launch of PiQo4 at 37th Annual Conference of the American Society for Laser Medicine and Surgery
Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, proudly announces its newest launch, PiQo4 – the most powerful advanced laser technology for tattoo removal and pigmentation. The technology will be showcased at the 37th annual American Society for Laser Medicine and Surgery (ASLMS) conference in San Diego, CA from April 5th – 9th, 2017.
Lumenis is Proud to Support the First International Scar Treatment Conference in Israel
Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, announced that it will be supporting the first International Scar Treatment Conference in Israel, which will be held in Tel Aviv, on February 22nd, 2017.
Treatments
Aesthetic treatments enabled by Lumenis laser devices allow doctors to provide a variety of treatments with outstanding results
Lumenis Proudly Showcases a Wide Range of Technologies for Multiple Skin & Body Applications at the 24th World Congress of Dermatology (WCD) 2019
Lumenis showcasing a wide range of novel technologies for skin, hair, body and women’s health applications at this year’s WCD, 11th – 14th June.
Bosley and Lumenis Partner to Introduce Breakthrough Hair Loss Solution, FoLix™, to the U.S.
Lumenis’ first-in-class, proprietary and FDA-cleared fractional laser technology for hair loss treatment has the power to transform the lives of millions of hair loss sufferers in the U.S.
Lumenis Introduces New Laser Hair Removal Solution, SPLENDOR X, at the 2018 American Society of Dermatological Surgery (ASDS)
Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, excitedly announces its newest launch, SPLENDOR X— the first solid state laser system equipped with the unique BLEND X technology for fast and effective hair removal and skin solutions. The technology will be showcased for the first time at the 2018 American Society of Dermatological Surgery – ASDS in Phoenix from October 11th-October 14th, 2018.
Mandy Moore Partners With Lumenis to Raise Awareness of Dry Eye Disease and OptiLight Treatment
Ms. Moore has partnered with Lumenis as a brand ambassador for OptiLight to tell her story and empower others. After suffering for years with dry, itchy, burning eyes, Ms. Moore learned her problem was dry eye disease—a condition that affects millions of people. After undergoing treatment with OptiLight, Ms. Moore’s quality of life greatly improved. OptiLight is a revolutionary, patented treatment that is the first and only light-based therapy for dry eye disease.